By Rob Curran
BioNTech, the German biotech that rose to fame when it partnered with Pfizer on a Covid 19 vaccine, named Novartis executive Ramón Zapata-Gomez as chief financial officer, succeeding Jens Holstein upon the latter's retirement in June.
The company had previously disclosed Holstein's plans to retire on June 30, at which time Zapata-Gomez, who has served as the chief financial officer of Swiss drug maker's Novartis's biomedical research unit since 2022.
Zapata-Gomez's experience will help BioNTech reinvent itself as a multi-product company with an emphasis on oncology, the company said. In addition to his work at Novartis, Zapata-Gomez has held financial positions at generic-drug maker Sandoz AG, and consumer-products giant Mondelēz International.
Write to Rob Curran at rob.curran@dowjones.com
(END) Dow Jones Newswires
May 05, 2025 06:54 ET (10:54 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。